Lv52
1520 积分 2022-09-20 加入
Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma
7小时前
求助中
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib
1天前
待确认
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
1天前
待确认
Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer
1天前
求助中
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
1天前
待确认
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1天前
待确认
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
1天前
待确认
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
1天前
待确认
Germline alterations in patients with lung cancer
4天前
求助中
Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events
4天前
已完结
皖公网安备34019202002308
